Originally developed as an anti-cancer agent, vorinostat is clinically approved for cutaneous T-cell lymphoma [42] and has been shown to reduce tumor growth and formation in pre-clinical models of metastatic bone cancer, uterine sarcoma, and estrogen receptor-negative mammary tumors [43,44,45]. This evidence concerns the gene ESR1 and primary cutaneous T-cell non-Hodgkin lymphoma.